The strong cash position and positive clinical data de-risk the pipeline significantly. The key catalyst to watch is the APEX Part B 16-week data expected in Q2 2026, which will determine the induction dosing regimen for Phase 3 trials. The stock should trade on clinical data readouts and pipeline expansion announcements rather than quarterly financial results.
Price Chart
Executive Summary
Apogee Therapeutics reported Q1 2026 results with a net loss of $74.1M, wider than the $55.3M loss in Q1 2025, driven by increased R&D and G&A spending. The key positive was the strong cash position of $1.3B following a $403M upsized public offering, extending runway into 2029, and positive pipeline updates including APEX Phase 2 Part A 52-week data showing durable maintenance with quarterly or less frequent dosing.
Key Facts
- Cash, cash equivalents, and marketable securities totaled $1.3B as of March 31, 2026, up from $902.9M at year-end 2025
- Completed $403M upsized public equity offering following positive Phase 2 APEX Part A readout
- Net loss widened to $74.1M in Q1 2026 from $55.3M in Q1 2025, driven by higher R&D ($60.8M vs $46.4M) and G&A ($22.0M vs $16.7M) expenses
- APEX Phase 2 Part A 52-week data showed durable maintenance: 75-85% of Week 16 EASI-75 responders maintained response at Week 52 with every 3- or 6-month dosing
- Phase 3 initiation in atopic dermatitis expected in H2 2026; APEX Part B 16-week data expected in Q2 2026
- Positive Phase 1b asthma results reported in January 2026; expansion into asthma and EoE trials planned
- Cash runway extended into 2029, through planned BLA filing for zumilokibart in AD
Financial Impact
Net loss of $74.1M in Q1 2026 vs $55.3M in Q1 2025; cash position strengthened to $1.3B from $902.9M
Risk Factors
- Clinical trial failure or disappointing data in upcoming readouts (APEX Part B, APG279 head-to-head)
- Dilution risk from potential future equity offerings to fund Phase 3 trials and commercialization
- Competitive pressure from existing therapies like DUPIXENT and other IL-13/TSLP targeting programs
- Regulatory risk: BLA filing and approval are not guaranteed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-215683 |
| Document: apge-20260511.htm | 0001193125-26-215683 |
| Document: 0001193125-26-215683-index-headers.html | 0001193125-26-215683 |
| Document: 0001193125-26-215683-index.html | 0001193125-26-215683 |
| Document: 0001193125-26-215683.txt | 0001193125-26-215683 |
| 8-K Data (Synthetic) | 0001193125-26-215683 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 15-12G | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 25-NSE | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 8-K | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Aug 11, 2026 7w ago | 8-K | $134.55 $134.71 | ▲ +0.12% | ▲ +0.56% | — |
Aug 10, 2026 7w ago | 8-K | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 10, 2026 7w ago | Press Release | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 6, 2026 8w ago | Institutional Cluster | $134.49 $134.45 | ▼ −0.03% | ▼ −1.24% | — |
Aug 3, 2026 8w ago | DEFA14A | $134.19 $134.69 | ▲ +0.37% | ▲ +0.47% | — |
Jul 11, 2026 11w ago | Insider Cluster | $133.82 $134.00 | ▲ +0.13% | ▲ +0.92% | — |
Jun 26, 2026 13w ago | DEFA14A | $132.61 $133.50 | ▲ +0.67% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access